Yes, there are specific mutations that lead to cross-resistance against both chemotherapy and radiotherapy.

To understand why, it is helpful to look at the shared goal of both therapies: **DNA damage.**
*   **Radiotherapy** works by creating Reactive Oxygen Species (ROS) that break DNA strands.
*   **Chemotherapy** (specifically cytotoxic types like platinums or alkylating agents) works by binding to DNA, causing breaks, or interfering with replication.

Therefore, mutations that allow a cell to **repair DNA faster**, **scavenge free radicals**, or **ignore the signal to commit suicide (apoptosis)** will create resistance to *both* modalities.

Here are the primary mutations and genetic alterations known to cause this cross-resistance:

### 1. TP53 (The "Guardian of the Genome")
This is the single most significant mutation regarding cross-resistance. The *TP53* gene produces the p53 protein, which triggers cell cycle arrest to allow for DNA repair or, if the damage is too severe, triggers apoptosis (cell death).

*   **The Mutation:** Loss-of-function mutations in *TP53*.
*   **Mechanism of Cross-Resistance:**
    *   **Chemo:** When chemotherapy damages DNA, a cell with mutant p53 fails to trigger apoptosis. Instead, it continues to divide with mutated DNA, leading to a more aggressive tumor.
    *   **Radio:** Radiation relies heavily on p53 to kill cells via the intrinsic apoptotic pathway. Without functional p53, the cells survive the radiation-induced DNA breaks.

### 2. KEAP1 and NFE2L2 (The Antioxidant Defense)
The *NFE2L2* gene encodes the transcription factor NRF2, which regulates the cell's defense against oxidative stress. *KEAP1* is the protein that normally degrades NRF2 to keep levels low.

*   **The Mutation:** Loss-of-function in *KEAP1* or gain-of-function in *NFE2L2*.
*   **Mechanism of Cross-Resistance:**
    *   **Radio:** These mutations lead to constitutively high levels of antioxidants (like glutathione). These antioxidants neutralize the Reactive Oxygen Species (ROS) created by radiation before they can damage the DNA.
    *   **Chemo:** NRF2 also upregulates drug efflux pumps (proteins that spit drugs out of the cell) and detoxification enzymes, rendering chemotherapy agents ineffective. This is frequently seen in Non-Small Cell Lung Cancer (NSCLC).

### 3. PIK3CA / PTEN / AKT (The Survival Pathway)
The PI3K/AKT pathway is a major survival signaling route in cells.

*   **The Mutation:** Activating mutations in *PIK3CA* or *AKT*, or loss-of-function mutations in *PTEN* (a tumor suppressor that shuts this pathway down).
*   **Mechanism of Cross-Resistance:**
    *   **Apoptosis Inhibition:** This pathway inhibits pro-apoptotic proteins (like Bad and Bax). Even if chemo or radio damages the DNA, the "survival signal" is so loud that the cell refuses to die.
    *   **Enhanced Repair:** AKT activation enhances Non-Homologous End Joining (NHEJ), a mechanism used to repair DNA double-strand breaks caused by radiation and certain chemotherapies.

### 4. EGFR (Epidermal Growth Factor Receptor)
While often associated with targeted therapy, *EGFR* mutations play a role in conventional resistance.

*   **The Mutation:** Constitutive activation (e.g., Exon 19 deletions or L858R).
*   **Mechanism of Cross-Resistance:**
    *   Mutated EGFR can translocate into the nucleus. Once there, it interacts with **DNA-PK** (a DNA repair enzyme). This interaction hyper-activates the DNA repair machinery, fixing the damage caused by both radiation and chemotherapy faster than the treatment can inflict it.

### 5. RAS (KRAS, NRAS, HRAS)
RAS mutations are among the most common drivers of cancer (especially pancreatic, lung, and colorectal).

*   **The Mutation:** Activating mutations (e.g., KRAS G12C).
*   **Mechanism of Cross-Resistance:**
    *   RAS mutations drive constant cell proliferation. However, they also increase the threshold for apoptosis. Cells with *KRAS* mutations have been shown to be inherently more resistant to radiation-induced cell death and platinum-based chemotherapy due to alterations in mitochondrial function and apoptotic signaling.

### 6. Bcl-2 Family (The Anti-Death Proteins)
While often driven by translocations (like t(14;18) in lymphoma) rather than point mutations, overexpression or mutation of these genes is a key factor.

*   **The Alteration:** Overexpression of *BCL2* or *BCL-XL*.
*   **Mechanism of Cross-Resistance:**
    *   These proteins sit on the mitochondria and physically block the release of Cytochrome C. Both chemotherapy and radiotherapy ultimately try to punch holes in the mitochondria to kill the cell; high levels of Bcl-2 act as a shield, preventing death regardless of the upstream damage.

### Summary of Cross-Resistance Mechanisms

| Gene Mutation | Function | Why it resists Chemo | Why it resists Radio |
| :--- | :--- | :--- | :--- |
| **TP53** (Loss) | Apoptosis Regulator | Cell refuses to die despite drug damage. | Cell refuses to die despite radiation damage. |
| **KEAP1** (Loss) / **NRF2** (Gain) | Antioxidant Response | Increases drug detoxification/efflux. | Neutralizes radiation-induced free radicals (ROS). |
| **PIK3CA / PTEN** | Survival Signaling | Inhibits apoptotic triggers. | Accelerates DNA double-strand break repair. |
| **EGFR** (Activation) | Growth Factor | Promotes survival signaling. | Translocates to nucleus to boost DNA repair enzymes. |

### A Note on "Acquired" vs. "Intrinsic" Resistance
It is important to note that tumors often evolve. A tumor might start sensitive to therapy, but under the selective pressure of chemotherapy, a sub-clone of cells containing a **TP53** or **KEAP1** mutation may survive, multiply, and result in a recurrent tumor that is now resistant to both further chemo and radiotherapy.